WO2005041877A3 - Method of inhibiting rejection following organ transplantation - Google Patents

Method of inhibiting rejection following organ transplantation Download PDF

Info

Publication number
WO2005041877A3
WO2005041877A3 PCT/US2004/035874 US2004035874W WO2005041877A3 WO 2005041877 A3 WO2005041877 A3 WO 2005041877A3 US 2004035874 W US2004035874 W US 2004035874W WO 2005041877 A3 WO2005041877 A3 WO 2005041877A3
Authority
WO
WIPO (PCT)
Prior art keywords
organ transplantation
rejection following
following organ
inhibiting rejection
organ
Prior art date
Application number
PCT/US2004/035874
Other languages
French (fr)
Other versions
WO2005041877A2 (en
WO2005041877A9 (en
Inventor
David M Briscoe
Marlies Reinders
Original Assignee
Childrens Medical Center
David M Briscoe
Marlies Reinders
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, David M Briscoe, Marlies Reinders filed Critical Childrens Medical Center
Publication of WO2005041877A2 publication Critical patent/WO2005041877A2/en
Publication of WO2005041877A3 publication Critical patent/WO2005041877A3/en
Publication of WO2005041877A9 publication Critical patent/WO2005041877A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The present invention is directed to methods for inhibiting organ/graft rejection. Preferably, the method comprises administering to a donor, prior to transfer of donor tissue, an effective amount of VEGF antagonist. The VEGF antagonist may also be administered to the organ recipient. In addition, an immunosuppressant and/or chemokine antagonist may also be administered to the organ donor and/or the recipient.
PCT/US2004/035874 2003-10-29 2004-10-28 Method of inhibiting rejection following organ transplantation WO2005041877A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51525403P 2003-10-29 2003-10-29
US60/515,254 2003-10-29

Publications (3)

Publication Number Publication Date
WO2005041877A2 WO2005041877A2 (en) 2005-05-12
WO2005041877A3 true WO2005041877A3 (en) 2005-06-16
WO2005041877A9 WO2005041877A9 (en) 2005-08-11

Family

ID=34549383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035874 WO2005041877A2 (en) 2003-10-29 2004-10-28 Method of inhibiting rejection following organ transplantation

Country Status (1)

Country Link
WO (1) WO2005041877A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20030215889A1 (en) 2002-03-20 2003-11-20 Simard J. Marc Non-selective cation channel in neural cells and methods for treating brain swelling
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
GB0427827D0 (en) * 2004-12-20 2005-01-19 Randox Lab Ltd Method of diagnosis
WO2008089103A2 (en) * 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
WO2008093246A2 (en) * 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
US20140050694A1 (en) * 2012-08-20 2014-02-20 Wisconsin Alumni Research Foundation Method of Treating Transplant Rejection and Autoimmune Diseases
WO2014189635A1 (en) * 2013-05-20 2014-11-27 The Trustees Of Columbia University In The City Of New York Tracking donor-reactive tcr as a biomarker in transplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547959A (en) * 1992-12-22 1996-08-20 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
WO1998051344A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547959A (en) * 1992-12-22 1996-08-20 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
WO1998051344A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Also Published As

Publication number Publication date
WO2005041877A2 (en) 2005-05-12
WO2005041877A9 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
WO2005107726A3 (en) Method for the treatment of back pain
WO2006001905A3 (en) A multilayer composite vascular access graft
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2005110481A3 (en) Prolongation of survival of an allograft by inhibiting complement activity
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
WO2006047841A3 (en) Engineering with homing factors
MXPA05008973A (en) Method of treating corneal transplant rejection.
IL157841A0 (en) Activation of natural killer cells by adenosine a3 receptor agonists
WO2002100148A3 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
DE60335202D1 (en) Chaperonin-10-immunosuppression
WO2005060960A3 (en) Use of histamine to treat bone disease
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2005089736A3 (en) Methods for treating inflammatory and autoimmune diseases
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
WO2009107088A3 (en) Method for producing an implantable bone composition
WO2003082203A3 (en) Elastin prevents occlusion of body vessels by vascular smooth muscle cells
WO2001045680A3 (en) Cd45 inhibitors
WO2004052305A3 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/22-22/22; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase